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Several RNA ligands that bind to feline immunodeficiency virus (FIV) reverse 
transcriptase (RT) were selected by Systematic Evolution of Ligands by 
Exponential Enrichment (SELEX) with recombinant FIV RT. Two of these 
ligands, F20 #53, and F18 #60 were potent inhibitors of recombinant FIV RT. 
Inhibition of RT was competitive with respect to template-primer and 
noncompetitive with respect to deoxyribonucleoside 5'-triphosphate substrates. 
SELEX ligand F20 #53 inhibited FIV derived from virus better than recombinant 
RT. In contrast, SELEX ligand FIB #60 was less inhibitory with virion RT as 
compared to recombinant RT. SELEX ligand F20 #53 was also more inhibitory 
in reactions with heteropolymeric templates than in reactions with 
homopolymeric template. Ligand F20 #53 also inhibited RT from a mutant of 
FIV resistant to 3'-azido-3'-deoxythymidine (AZT). 
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General Introduction 
Human immunodeficiency virus 1 (HIV-1 ) is an RNA virus that belongs to 
the lentivirus family of non-oncogenic, cytopathic retroviruses (9). HIV-1 has 
properties similar to prototypic animal lentiviruses including simian 
immunodeficiency virus and feline immunodeficiency virus (FIV) which infect 
rhesus macaques and cats, respectively. These animal models may prove useful 
in the understanding and the treatment of acquired immunodeficiency 
syndrome (AIDS) (10). 
Antiviral agents are usually targeted against an enzyme or other viral 
component that is instrumental in replication of the virus. Current efforts in 
AIDS chemotherapy are focused on interruption of the virus life cycle by 
inhibiting reverse transcriptase (RT), viral protease, or other viral proteins (35). 
However in clinical treatment of patients there is a rapid emergence of 
resistance to the drugs that inhibit RT (35). Kaplan et al. have also found viral 
resistance to protease therapy in vitro (15). This rapid emergence of drug 
resistance makes new strategies for drug design important. Systematic 
Evolution of Ligands by Exponential enrichment (SELEX) is a novel approach 
that may provide strategies to combat resistance (46). This process rapidly 
selects for ligands which have a high affinity for target enzymes. The purpose 
of this project was to characterize SELEX ligands which had been selected to 
bind to FIV RT. In order to study the modes of inhibition of RT by SELEX 
ligands, assays to be developed that utilize natural FIV RNA and DNA templates. 
FELINE IMMUNODEFICIENCY VIRUS 
Feline immunodeficiency virus is a lentivirus that has been shown to 
cause an AIDS-like syndrome in cats. This system provides a useful animal 
model for the study of AIDS (1, 29). The FIV system possesses economical 
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and practical advantages over other animal models, such as the low cost of 
animal care, ease of in vivo studies, and the safety of working with a virus that 
does not infect humans (1, 10, 29). 
Pathogenesis. Like HIV-1 infection of humans, FIV infection of cats can be 
characterized by a series of five stages. The five stages for FIV infection are: 
acute infection, asymptomatic carrier, persistent generalized lymphadenopathy, 
AIDS related complex, and AIDS (28). 
The primary phase of the FIV infection is characterized by variable 
degrees of fever, neutropenia, and generalized lymphadenopathy. After 
disappearance of the early clinical signs of disease, experimentally-infected cats 
enter a lengthy period of virus latency (no clinical signs of disease manifested) 
during which FIV can still be isolated from the blood. The third stage of 
infection is equivalent to the persistent generalized lymphadenopathy stage in 
HIV-1 infected humans. This stage is characterized by vague signs of disease in 
the absence of obvious infection. The fourth stage is reminiscent of the AIDS 
related complex (ARC) in humans. Cats with ARC-like illness have chronic 
secondary infections at one or more body sites. If the cat survives stage four 
(fewer than 10% do) then the cats exhibit a clinical picture that can be defined 
as AIDS-like. Cats with AIDS-like illness, similar to their human counterparts, 
often have weight loss (>20% lost) opportunistic infections in multiple body 
sites, and most are anemic and leukopenic (28). 
Life cycle. The life cycle of FIV is typical of a retrovirus. Following attachment 
and entry into a cell, one or both copies of RNA are converted to double-
stranded DNA by RT and this DNA is integrated into the hosts genome by 
another virus encoded-enzyme, integrase. This integrated viral DNA is called 
a provirus. The provirus is transcribed by cellular DNA-dependent RNA 
polymerases to generate structural genes, {gag, po/ and en\/} and full length 
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Figure 1. The life cycle of a retrovirus. 
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RNA copies which are used as genomes for progeny virus (Fig 1). Viral gene 
expression requires the action of regulatory proteins such as Rev and Tat, which 
controls expression of viral genes. The proviral DNA remains a permanent 
component of the host cell genome and is passed to all daughter cells (45). 
There are many points in the life cycle that offer targets for 
chemotherapy. Approaches to HIV-1 therapy have targeted a number of these, 
including attachment, enzymes such as RT, and protease (35), and regulatory 
the proteins, such as Tat and Rev (12). 
The most successful target for AIDS therapy has been RT. All of the 
drugs that have been approved for AIDS therapy in humans target this enzyme. 
These include 3'- azido-3'-deoxythymidine, (AZT), 2',3'-dideoxyinosine (ddl), 
2'3'-dideoxycytidine (ddC), and 2',3'-dideoxy-2',3'-didehydrothymidine (d4T). 
(35, 37, 42). These nucleoside analogues have modifications at the 3' position 
on the deoxyribose. Incorporation of these analogues blocks 5'->3' elongation 
during polymerization and result in chain termination (31). 
Biochemical features of RT. North et al. have purified and extensively 
characterized the FIV RT. FIV RT has been shown to be similar to HIV-1 RT in 
physical properties and in catalytic functions (22, 23, 25,). FIV RT, like HIV-1 RT 
has three catalytic functions. It has RNA-dependent DNA polymerase, DNA-
dependent DNA polymerase, and RNase H activities (7, 34). The FIV and HIV-1 
RTs have a similar requirement for IVIg^+ and similar template specificities. The 
p61-p55 heterodimer that is observed with HIV-1 RT is similar to that of the FIV 
RT. The RT activity of FIV, like HIV-1, is comprised of a heterodimer of two 
subunits which have common amino-termini (8). The larger subunit contains 
the RNase H domain of RT. 
The genes encoding RTs of FIV and HIV-1 also exhibit considerable 
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sequence homology. When the predicted amino acid sequence of FIV RT was 
compared to that of HIV-1 RT, a 60% identity was observed (26, 44). These 
similarities make FIV RT an attractive model for the study of RT-targeted therapy 
of human AIDS. 
Kinetic mechanism of RT activity. RT catalyzes the synthesis of DNA via an 
ordered kinetic mechanism in which template-primer binds to the enzyme 
before the first 2'-deoxynucleoside 5'-triphosphate is used for primer elongation 
(31). Phosphodiester bond formation proceeds with inversion of configuration 
at the «-phosphorus, indicating that the 3'-hydroxyl group of the primer 
terminus attacks the a-phosphorus of the 2'-deoxynucioside-5'-triphosphate 
substrate without intervening formation of a covalent enzyme intermediate (31). 
The steady-state and pre-steady-state kinetics of incorporation of 
nucleotides and nucleotide analogues into a defined RNA template sequence 
primed with DNA has been examined. The kinetic mechanism that explains the 
potent inhibition by chain terminating nucleotide analogues such as AZTTP, 
ddATP and ddCTP has been determined. The mechanism of AZTMP proceeds 
as follows; The steady state rate of AZTMP incorporation into the 3'-primer 
terminus is limited by the rate of dissociation of the chain-terminated template 
primer from the enzyme. This slow rate of dissociation leads to the steady-state 
accumulation of RT chain-terminated template-primer complex and results in 
potent inhibition of the enzyme (31). Inhibition constants have been determined 
for several nucleotide analogues, such as, ddATP, and ddCTP, which act by the 
same mechanism as AZTTP for HIV-1 RT (5). 
North et al. have shown substantial similarities in the kinetic constants for 
the inhibition of HIV-1 RT and FIV RT by nucleotide analogues, including, 2',3'-
dideoxythymidine 5'-triphosphate (ddTTP), AZTTP and 2',3'-dideoxy-2',3'-
didehydrothymidine 5'-triphosphate (D4TTP) (6, 22, 24, 25). The nucleotide 
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analogues were all competitive with respect to variable substrate concentration. 
Inhibition constants for these nucleotide analogues with FIV RT and HIV-1 RT 
are given in Table 1. 
Table 1. Inhibition of FIV RT and HIV-1 RT by nucleotide analogues*. 
Mean K. ± SD fnM) Mean IC/IC ratio 
Inhibitor FIV HIV FIV HIV 
AZTTP 6.2±1.2 6.5±1.8 0.0010 0.0011 
dTTP 6.7±3.3 5.9±4.2 0.0020 0.0010 
D4TTP 1.8±0.7 8.3±0.8 0.0005 0.0014 
^values are from North et al. (6, 22, 24). 
Inhibition constants for a non-nucleotide analog, phosphonoformic acid 
(PFA) have also been determined. PFA is an antiviral drug that inhibits DNA 
polymerases, including RT, by blocking the pyrophosphate exit site (40). PFA 
has been found to be a noncompetitive inhibitor of HIV-1 and FIV RTs with 
respect to a variable substrate concentration, and it yields similar inhibition 
constants with these two enzymes (24). 
In order to compare activities of FIV and HIV-1 RT further, North et al. 
have examined template specificities which are summarized in Table 2. Both 
enzymes are able to utilize poly(rA)-oligo(dT)io, poly(rl)-oligo(dC)io and poly(rC)-
oligo(dG)io- Both enzymes fail to utilize poly(rU)-oligo(dA)io, and poly(rG)-
oligo(dC)io. The two most effective template-primers are poly(rA)-oligo(dT)io, 
and poly(rl)-oligo(dC)io (23). 
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Table 2. Template specificity of FIV and HIV RT*. 
Template FIV HIV 
% relative activity ± SD 
poly(rA)-oligo(dT)io 100 100 
poly(rU)-oligo(dA)io 0.1 0.29 
poiy(rC)-oligo(dG)io 46 ± 4 15 ± 1.5 
poly(rG)-oligo(dC)io 0.34 ± 0.6 0.16 ± 0.1 
poly(rl)-oligo(dC)io 109 ± 7.8 76 ± 1.8 
* Values are from North et al (23). 
The characterization of these templates has allowed studies of ddCTP, 
ddGTP, AZTTP, ddTTP, and PFA. These homopolymeric templates do not allow 
the study of dATP analogues such as ddATP. However, Cronn et al. and North 
et. al have studied heteropolymeric templates such as M13 and 0X174, in order 
to study ddATP (7, 25). The activity of FIV RT with these DNA templates was 
only 10-20% of that obtained with poly(rA)-oligo(dT)io as template primers. 
None of the heteropolymeric RNA templates tested were efficiently used by FIV 
RT. 
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DRUG RESISTANCE 
Drug resistance is a limiting factor in the treatment of AIDS. AZT was the 
first drug approved and used for treatment of AIDS (21), and clinical isolates of 
HIV-1 that are resistant to AZT are detected in patients treated six months or 
longer with AZT (17, 36). Subsequently, mutants of HIV-1 resistant to ddl and 
ddC have been reported (13, 35, 43 ). Mutants resistant to several other 
inhibitors such as ddGTP, (30) and protease inhibitors (15, 27, 35) have been 
selected in vitro. It is likely that resistance will arise with most, if not all, 
therapeutic approaches. 
Resistance of HIV-1 to AZT, is due to mutations which map in the pol 
gene (35). Similarly, resistance to other drugs such as ddl and ddC, have also 
been mapped in the pol gene of HIV-1 (35). Our lab was the first to report the 
selection of an AZT-resisant mutant retrovirus in a cell culture system (32). As 
in HIV-1, AZT-resistant mutants of FIV have mutations in poi. FIV systems are 
more versatile then HIV-1 systems for the study of drug resistance because FIV 
mutants are selected more easily then HIV-1 mutants (35). FIV also is a safer 
virus to work with than HIV-1. These features make FIV an attractive model for 
studies of resistance for AIDS therapy. 
Many strategies to combat drug resistance have been proposed. The 
major focus is on combination chemotherapy. However, even with the 
combination of AZT and ddl, or ddC resistant mutants of FIV and HIV-1 arise 
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(11, 41, 49) Therefore it is desirable to find drugs or strategies to minimize 
resistance. SELEX is a novel approach which may offer an immediate strategy 
to combat resistance. 
SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT 
SELEX is a novel method to rapidly select preferred binding ligands from 
a population of random RNA oligonucleotides. Inherent in the SELEX technique 
is the specificity of the RNA to the target enzyme (46). Another important 
advantage is that RNA may be less cytotoxic than the traditional nucleoside 
analogues, which are cytotoxic at high doses. 
The SELEX method relies on the mechanism that is usually associated 
with evolution, that is, variation, selection, and replication (46). An overview of 
this procedure is given in Figure 2. First, a pool of RNAs that are completely 
randomized at specific positions are subjected to selection for binding to a 
target, in this case to purified recombinant FIV RT on nitrocellulose filters. 
Second, the selected RNAs are eluted and converted back to DNA by reverse 
transcription, and are amplified as double-stranded DNA by PGR. This DNA is 
then used for in wfro transcription by T7 RNA polymerase The resulting DNA is 
enriched for those sequences which bind FIV RT. The selected RNA is then 
used to begin the next cycle. More stringent conditions can be used in 
subsequent cycles to select the ligands that bind with greatest affinity. 
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fandomized template construction cloning, analysis 
À 
PGR amplification 
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DNA 
in vitro T7 transcrip 
ssDNA SELEX RNA population 
cONA synthesis selection 
enriched RNA population 
Figure 2. An overview of the SELEX selection procedure. (Starting at the top, 
going cloclcwise) Randomized template construction (46). In vttro transcilpllai of 
the pool of oligonucleotides. Binding of oligonucleotide to target protein 
resulting in an enriched RNA population. cDNA synthesis by reverse 
transcriptase. Second strand synthesis and polymerase chain reaction (PCR) 
amplification. In vttio transcrlpfton to begin the next round of selection (46). 
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This approach has been employed to develop inhibitors of HIV-1 RT (47). 
The RNA ligands, although not kineticaily characterized, have been shown to 
inhibit HIV RT specifically, and not RTs from avian myoblastosis virus, Maloney 
murine leukemia virus, or HIV type 2 (47) A gel-based assay was used in those 
studies to measures concentrations which inhibit RT activity by 50 % (ICgo). The 
IC50 for inhibition of HIV-1 RT by the RNA ligand was approximately 100 nM 
(47). In a collaboration with Dr. Larry Gold's lab (University of Colorado), SELEX 
ligands have been made that inhibit the FIV RT (3). 
Selection of ligands that bind FIV-RT. High affinity ligands were selected from 
an RNA repertoire containing 10^"* unique species with a 40 base long random 
RNA sequence. These selections were carried out by Hang Chen and Larry 
Gold, Univerisity Colorado. The first ten rounds of selection were performed by 
nitrocellulose filter partitioning. The last eight rounds were performed by native 
gel shift assays. After 18 rounds of selection, the binding affinity of the 
selected RNA pool could not be further improved by continued selection. The 
FIV RT binding affinity of RNA from the eighteenth round of selection (Kd 7.7 
nM) was at least 10^-fold higher than that of the starting repertoire (Fig 3) (3). 
RNA sequences were obtained from eighty clones derived from the 
eighteenth round of selection and these were analyzed by an RNA folding 
algorithm. 
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100 
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Protein Concentration (nM) 
Figure 3. Binding of RNA from indicated rounds of SELEX to FIV RT. Open 
circles represent the starting pool of random RNA, Kd too high for accurate 
determination. Open squares represents RNA from round six, Kd too high for 
accurate determination. Closed circles represents round 10 with a Kd of >100. 
Closed squares represent round 14 with a Kd of 13.6. Open triangles, round 16, 
Kd is 8.7. Closed triangles represent round 18 with a Kd of 7.7 (3). 
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Figure 4. Predicted folding of the FIV RT-specific SELEX Iigands. The secondary 
structure was predicted by folding programs (3). 
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The selected RNA molecules fell Into three major classes (Fig 4){3). Class I 
molecules form stem-loop structures or stem-loops with an internal bulge, and 
contain two U-tract consensus sequences present in the region predicted to be 
single stranded. Three subsets of class I ligands also have an ACG consensus 
in the loop. Class II consists of three subsets of species which could form stem-
loops with internal bulges. Class III are A-rich and appear to be unstructured as 
predicted by the RNA folding program (50). 
Seven representatives of the eighty FIV-specific ligands were obtained 
for further studies. A major goal of this work was to characterize the inhibition 
of FIV RT by those seven SELEX ligands. 
ENDOGENOUS TEMPLATES 
As will be discussed below, the inhibition of FIV RT by SELEX ligands is 
competitive with respect to template-primer. This is in contrast to the existing 
antiviral nucleoside analogues, whose 5'-triphosphates compete with a dNTP 
substrate. Virtually all work with RT has been with homopolymeric RNA 
templates, which has been adequate for studies of the nucleotide analogues. 
However, for the study of SELEX ligands that compete with template-primer for 
binding to RT (3), more biologically relevant, heteropolymeric templates are 
needed. There is very little information available on use of heteropolymeric 
templates for kinetic studies of RT. Characterization of SELEX ligands with such 
template-primer systems requires development of new assay systems for FIV RT 
14 
In the past, only a few attempts have been made to use heteropolymeric 
templates. DNA from phages 0X174 and Ml3 are two heteropolymeric 
templates that have been used in the kinetic studies of FIV RT (7, 25). RT had 
somewhat lower activities with these templates than with the standard 
homopolymeric template, poly(rA)-oligo(dT)io (7, 25). Attempts to use 
heteropolymeric RNA templates, including 23S rRNA primed with 
oligodeoxyribonucleotides, and poly(A)+mRNA primed with oligo(dT) were 
unsuccessful due to the low activities of RT [less than 2% of that with poly(rA)-
oligo(dT)io] with these templates (7). 
Endogenous RNA and DNA templates have been made for some studies 
of HIV-1 RT (16, 31). Reardon used short oligonucleotides approximately 50 
bases long in order to kinetically analyze the RNA-dependent and DNA-
dependent activities of HIV-1 RT (31). Klarman et al. have made substantially 
larger templates, approximately 1.6 kb in length, in order to study template-
directed pausing of DNA synthesis with HIV-1 RT (16). These authors found 
that certain sequences of HIV-1 RNA and DNA contain strong pause and stop 
sites for polymerization in vitro. This may explain why some template-primer 
systems are not suitable for kinetic studies of FIV RT. Klarman et al. also 
showed that RT dissociates from the primer template at some pause sites and 
remains bound at others. These data suggest that when designing endogenous 
templates care has to be taken to find sequences that don't contain strong 
pause sites (16). 
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All of the previous work that has been done with endogenous template 
systems has focused on studies of reaction mechanisms or the fidelity and 
procestivity of RT (16, 31). There have been no previous studies of ligands that 
compete with the template-primer binding site on RT. A major goal of this work 
is develop and characterize endogenous templates that can be used in studies 
of RT-targeted antivirals, including SELEX ligands. 
GOALS 
The goals of this study were to evaluate seven SELEX ligands as 
inhibitors of FIV RT and study the kinetics of inhibition by the ligands that were 
the most potent inhibitors. 
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MATERIALS AND METHODS 
MATERIALS 
Enzymes. Recombinant FIV RT was purified by a method that has been 
developed by North, et al., (25). Wild-type and AZTTP-resistant FIV RTs were 
also purified from virions by a procedure described in North, et al. (23). T7 RNA 
polymerase, human placenta RNase inhibitor, and RNase-free RQ1 DNase were 
purchased from Promaga, Madison Wl. Thermusaquat'cusDHA polymerase was 
purchased from Perkin Elmer Cetus, Norwalk CT. 
Chemicals. Diethylpyrocarbonate (DEPC), phosphonoformic acid (PFA), 2',3'-
dideoxycytidine 5'-triphosphate (ddCTP), and Triton X-100 were purchased from 
Sigma Chemical CO. St Louis, MO. AZTTP, the 5'-triphosphate of AZT was 
provided by Wayne Miller, of Burroughs Wellcome Co., Research Triangle Park, 
NC. Poly(rA)-oligo(dT)io, and Poly(rl)-oligo(dC)i2.i8 were purchased form 
Pharmacia LKB, Piscataway, N.J. [Methyl-^H]d'TTP, and [5,-5'-^H]dCTP were 
obtained from Dupont-New England Nuclear, Boston MA. Geneamp PCR core 
reagents were purchased from Perkin Elmer Cetus, Norwalk, CT. All other 
chemicals were reagent grade or better. 
Preparation of SELEX Uganctë 
RNase free environment. All reagent and equipment were treated with DEPC 
or baked at 100 °C whenever possible to ensure that RNase-free materials were 
used. 
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PCR Amplification. Amplification of DNAs expressing SELEX ligands were 
performed using a Perkin Elmer DNA thermocycler 410. The cassette to be 
amplified (Fig 5) had the following sequence; 5'-GGGAGGAUGUUUUCUCAGA-
CCGUAA-N40-UUGCAGGAUCGUGAAGUAGGAUCCGGG-3'where N40 represents 
the randomized portion of the SELEX ligand. The 5'-end is primed with primer 
designated as CH2 (5'-CCCAGCTTAATACGACTCACTATAGGGAGGATAT-
TTTCTCAGACC-3') and the 3' end is primed with primer designated as CH3 (5'-
CCCGGCTCCTAGTTCACGATGCTGCAA-3')- Each 100 ^1 reaction contained 10 
mM Tris-HCI, pH 8.4, 50 mM KCI, 0.75 mM MgClj, 0.05 mg/ml bovine serum 
albumin, 1 mM of each dCTP, dATP, dGTP, and dTTP (dNTP), 0.25 pmoles/jul of 
each primer CH2 and CH3, and 0.025U/;j1 Taq DNA polymerase. The PCR 
amplification was run for 25 cycles. Each cycle consisted of 94°C for 30 seconds 
for denaturation, 54°C for 20 seconds for annealing, and 72°C for 90 seconds for 
elongation (33). The DNA from the PCR amplification was used directly for in vitro 
transcription. 
In WfrD transcription. RNA ligands were transcribed from the amplified DNA in 
vitro. Reactions were run in a total volume of 100 pi\ that contained 40 mM Tris-
HCI, pH 8.0, 12 mM MgClg, 5 mM dithiothreitol, 1 mM spermidine, 20% W/V 
polyehtylene glycol (MW 8000), 0.01% V/V Triton X-100, 0.2 mM each of CTP, 
ATP, GTP, and UTP, 20U RNase inhibitor RQ1, 100 U T7 RNA polymerase, and 
25^1 (approximately 700 pM) of PCR product (20). The reaction was run at 37 °C 
for four hours. 
18 
A. IN WRO CASSETTE. 
GCTAATACGACTCACTATAGGGATAUUUUCUCAGACCGUAA-N^-UUGCAGCAUCGUGAACUAGGAUCCGGG-3' 
3'-AACGTCGTAGCAC TTGATCCTAGG CCC-5' 
B. SELECTED RNA LIGANDS (ONLY THE VARIABLE REGION SHOWN) 
F20TH #60 5'-GUACCGAAUGUGCUUUUGGCCGAUUUUUGGCCCCUGCAG-3' Kd=1.9 nM 
F20TH #34 5'-AACUUUUGUGGCUUCACGACCACCAUUUUUGUGUUGUAA-3' Kd=6.1 nM 
F20TH #82 5'-CUACUUCAACCACCAGGGAGCAGAUGACUCCAUCAGCAU-3' Kd=6.0 nM 
F18TH #11 5'-CACUAAGCAGAUACCGAAAGACUUGCCCGCAACACGCAA-3' Kd ND 
F18TH #13 5'-GCGUGGACUGGUCCAUGCACCAUUGACACUUGAUCCACC-3' Kd ND 
F18TH #53 5'-UUGCGAAGGAAAAACCGACCUGCUUUACGCGUCAAUAUG-3' Kd=4.5 nM 
F18TH #66 5'-ACUAAGAAUUGAUGUGGAUCUGAGUAACACGUACAAUCA-3' Kd ND 
Figure 5. In vitro cassette, and sequence of the selected RNA ligands. A) In yttro 
cassette. Underlined at the 5'-end is a T7 promoter sequence. The 3'- end is a 
PCR primer sequence. B) Sequence of selected RNA ligands. 
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Reactions were stopped by addition of, 100 jui 7M urea, TBE [0.0045 IVl Tris-
Borate, 0.001 M Ethylenediaminetetraacetic acid (EDTA) pH 8.0], containing 
0.05% Xylene cyanate, and 0.05% bromophenoi blue, and samples were heated 
at 90 °C for three minutes. The samples were then loaded onto a 7M urea, 10% 
polyacrylamide gel and the gels were run at 600 volts for 30 minutes. RNA 
was located by UV shadowing. RNA was eluted from the gel with two volumes 
of 2mM EDTA, and one volume of 3M sodium acetate. RNA was separated 
from gel material by filtration through a 0.22 jum acetate syringe filter. The 
filter was washed with 5 volumes of 100% ethanol. Samples were frozen in 
liquid nitrogen for 15 minutes, then thawed and the RNA was pelleted by 
centrifugation at 13,000 x g for 15 minutes. The pellet was dried by a speed 
vacuum and resuspended in DEPC-treated water. Concentrations were 
calculated by the following formula: [RNA] p moles/1 =(1000 x ODggo x dilution 
factor X 33)/{320 x92)). Where 1000 is the unit conversion factor to p moles of 
RNA, one OD unit is 33 pg/ml, 320 is average molecular weight of a nucleotide 
and 92 is the length of the RNA ligand. 
PreparaHon of RNA and DNA temptates 
PGR amplification. For preparation of DNA and RNA templates, the PGR 
reagents were the same as for SELEX PGR amplifications, except that different 
primers and DNA templates were used. These templates were made from the 
FIV molecular clone, 34TF10, which contains a cloned provirus of FIV inserted 
into the plasmid pUG119 (44). In order to enable synthesis of the RNA template 
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a primer designated as 24' with ttie following sequence was used; 5'-
CCCAGCTTAATACGACTCACTATAGGAGTCC-AGAAGATAAATTACAGG-S'.This 
primer contains the promoter for T7 RNA polymerase (underlined), which allowed 
in vifro transcription of the PGR product. The other primer used, designated as 
#14 was (5'-GGGGTCATAGTATCCTAGTTG-3'). These primers amplified a 316 
(corresponding to nt. 2979-3295) base-pair region of the RT encoding region (44). 
In vttro transcription of RNA template. In vitro transcriptions were performed 
under the same conditions as for in W/ro transcription of SELEX ligands. 
Gel purification of RNA template. Gel purification of the RNA template was the 
same as used for the purification of SELEX ligands. 
Asymmetric PGR amplification for the preparation of DNA template. To prime 
the 5' end of the DNA a primer designated as #24 (5'-
CTCCAGAAGATAAATTACAGG-3') was used. Primer #14 concentration was 1/50 
that of #24 in order to preferentially amplify only one strand. 
Single stranded DNA purification. DNA from asymmetric PGR was purified by 
QIAquick spin PGR purification kit (Qiagen, Chatsworth, CA.). This procedure 
allows rapid purification with a 90% yield of single stranded or double stranded 
DNA PGR products. 
Primer annealing. DNA and RNA templates to be used in RT assays, were 
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primed with PCR primer #14. This was done using a Perkin Elmer DNA 
thermocycler 410. The primer was added in a 2:1 molar ratio to the respective 
templates. The template primer mix was then heated at the following 
temperatures; 90 °C for 30 seconds, 60 °C for 15 minutes, 37 °C for 15 minutes, 
25 °C for 15 minutes and 4 °C for 15 minutes. All template-primers were stored 
at -20 °C until used. 
RT assays. RT was assayed essentially as described by North et al (23, 25). 
Reactions were carried out in a volume of 50 ji\ which contained 50 mM Tris-
HCI, pH 8.5, 10 mM dithiothreitol, 0.05% Triton X-100, 250 jug of bovine serum 
albumin (nuclease free) per ml, 6 mM MgClg, 80 mM KCI, 20 ^M [Me/hy^-^H]dTTP 
[used in reactions with 0.5 Aggo U with poly(rA)-oligo(dT)io, endogenous DNA or 
RNA template-primers), or [5'-5-^H]dCTP [used in reactions with 0.5 Ageo U 
poly(rl)-oligo(dC)io.i8] and approximately 5 U of RT enzyme. Aliquots of 40 fjl 
were taken at the indicated times and spotted onto filters (no. 3, 2.3-cm 
diameter; Whatman, Inc., Clifton N.J.) that had been presoaked with 5% 
trichloroacetic acid-1% sodium pyrophosphate. Filters were then washed four 
times, at least 1 hour each, in ice cold 5% trichloroacetic acid-1% sodium 
pyrophosphate and once in 95 % ethanol, dried and counted in liquiflour (Dupont 
NEN research products, Boston MA). Kinetic parameters (Km and Ki) were 
determined in reactions with [dTTP] varied from 2.0 to 20 jjM and [template] 
varied from 0.5 to 0.012 A260 U. Intercept values calculated from double 
reciprocal plot were used to obtain kinetic parameters (22, 24). Values reported 
are averages from at least duplicate determinations. 
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RESULTS 
Initiai screening of the SELEX ligands. SELEX ligands were prepared by in vitro 
transcription and gel purification as described in the Material and Methods 
section. The ligands were each tested for the ability to inhibit FIV RT, and Ki 
values were determined with variable concentrations of dTTP as substrate, 
poly(rA)-oligo(dT)io as a template-primer, and purified recombinant FIV RT as 
enzyme (Table 3). Two ligands F20 #60 and F18 #53 were potent inhibitors of 
FIV RT with Ki values of 108 and 89 nM, respectively. Their structures are shown 
in Figure 5. The other five ligands were less inhibitory and had Ki values greater 
than 1000 nM. A Lineweaver-Burke plot for inhibition of recombinant FIV RT by 
F18 #53 with variable dTTP is shown in Figure 6. All ligands tested were similar 
in that they were noncompetitive inhibitors of RT with respect to dTTP. 
TABLE 3. Ki DETERMINATIONS FOR SELEX LIGANDS* 
SELEX LIGAND Ki (nM) 
F20 #60 107 ± 18 
F20 #82 >1000 
F18#11 >1200 
FIB #13 >3200 
F18 #53 89 ± 18 
F18 #66 >1000 
F18#39 >1000 
* Ali experiments were performed with poIy(rA)-oligo(dT)^o used as the template-
primer. Each value represents a mean Ki value with 6 determinations per value. 
23 
0.5 -0.4 -0.3 -0.2 -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 
1/[dTTP] (|jM)-i 
Figure 6. Lineweaver-Burke Plot for inhibition of Recombinant FIV RT by SELEX 
ligand F18 #53. Concentration of F18 #53 were 200 nM (•) 100 nM (A) 50 (•) 
and no inhibitor (•). 
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SELEX specificity. All seven SELEX ligands were specific for FIV RT. They did 
not inhibit HIV-1 RT (data not shown), and did not bind to AMV and MMLV RTs 
(3). 
Inhibition of FIV RT by SELEX ligand F18 #53. The SELEX ligand that had the 
lowest Ki value, F18 #53 (#53) was further characterized using three different FIV 
RTs. These were the purified recombinant RT (which was the enzyme the ligand 
was selected with), the purified RT from virions of wild-type FIV, and the RT from 
a AZT-resistant FIV, designated as virion-AZR-17c (33). Reactions were carried 
out with variable template-primer [poly(rA)-oligo(dT)io] and variable dTTP (Table 
4). Competitive inhibition was seen with variable concentration of template-
primer, and noncompetitive inhibition was observed with variable concentration 
of dTTP (Figure 7). Interestingly, the ligand #53 inhibited both wild-type RT and 
AZR-17C, (Ki values of 37 and 44 nM respectively) better than the recombinant 
RT (Ki value of 89 nM) It is important to note that there was no appreciable 
difference, between the AZTTP-resistant RT from AZR-17c and wild-type RT in 
susceptibility to this SELEX ligand. 
Inhibition of FIV RT by SELEX ligand F20 #60. Ligand F20 #60 (#60) inhibited 
purified recombinant FIV RT with a Ki comparable to that of #53. This ligand 
was further characterized using variable template-primer (poly(rA)-oligo(dT)io and 
purified wild-type-virion FIV RT (Table 5). 
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Figure 7. Lineweaver-Burke plots showing modes of inhibition using SELEX 
ligand #53. Concentrations of #53 were 200 nM, (À) 50 nM (•) and no #53 (•). 
A) Noncompetitive inhibition with variable dTTP concentration and recombinant 
FIV RT. B) Competitive inhibition with variable poly(rA)-oligo(dT)io concentration 
and recombinant FIV RT. C) Noncompetitive inhibition with variable dTTP 
concentration and wild-type-virion FIV RT. D) Competitive inhibition with variable 
poly(rA)-oligo(dT)io concentration and wild-type-virion FIV RT. 
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TABLE 4. 
Ki DETERMINATIONS FOR INHIBITION OF FIV-RT BY SELEX LIGAND #53* 
ENZYME VARIABLE Ki (nM) ± SEM 
Recombinant FIV RT dTTP 89 ± 18 
Recombinant FIV RT poly(rA)-oligo(dT)io 95 ± 7 
Virion-wild-type FIV RT dTTP 37 ± 4 
Virion-wild-type FIV RT poly(rA)-oligo(dT)io 31 ± 2 
Virion-AZR-17c RT dTTP 44 ± 4 
Virion-AZR-17c RT poly(rA)-oligo(dT)io 26 ± 7 
*AII reactions were run with poly(rA)-oligo(dT)io as a template-primer. Each value 
represents a mean Ki value with six determinations per value. 
The mode of inhibition is competitive with variable template concentration and 
noncompetitive with variable nucleotide concentration (data not shown). In 
contrast to #53, #60 inhibited virion-wild-type FIV RT about three fold less than 
recombinant FIV RT. Due to the poor inhibition of virion-derived RT, #60 was not 
further characterized. 
In order to further characterize #53, because of the competitive type of 
inhibition with template-primer substrate, a more biologically relevant template-
primer was needed. 
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TABLE 5. 
Ki DETERMINATIONS FOR INHIBITION OF FIV-RT BY SELEX LIGAND #60* 
ENZYME VARIABLE Ki (nM) ± SEM 
Recombinant FIV RT dTTP 
Recombinant FIV RT poly(rA)-oligo(dT ) io 
107 ± 18 
120 ± 7 
Virion-wild-type FIV RT dTTP 334 ± 4 
* Ali reactions were run witii poly(rA)-oligo(dT)io as a template-primer. Each value 
represents a mean Ki from six determinations. 
Construction of an endogenous RNA Template. The RNA template was made by 
amplification of a region of the FIV genome from a plasmid containing 34TF10 
which has the FIV provirus cloned into pUC119 (44). Primers that amplify a 316 
base-pair portion, bases 2979-3295, of the RT-encoding region were used. A T7 
RNA polymerase promoter sequence was added at the 5-end of the forward 
primer (24') to enable In vitro transcription of the PCR product (Fig 8). This 
provided an RNA template that could be used for RT assays. The primer used for 
RT assays with this template was primer #14 which was used for PCR 
amplification in the reverse direction. 
Under the conditions stated in the Materials and Methods section {"in vitro 
transcription of RNA templates") approximately 2680 nmoles of RNA were 
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recovered. The RNA template was then primed with primer #14 (Fig 8) at 
various primer-template molar ratios to find the optimal conditionsfor RT activity. 
A template:primer ratio of 1:7 gave maximal RT activity (Fig 9 A). This 
template:primer ratio was used in all subsequent RT the assays. 
Construction of the DNA Template. The DNA template was constructed by 
asymmetric PGR as described in Materials and Methods. A typical yield was 
2500 nmoles. This template was primed with the PGR primer #14 (Fig 8) and the 
optimal template to primer molar ratio for RT activity was determined to be 1:9 
(Fig 9 B). 
Characterization of reactions with endogenous RNA templates. The velocity of 
FIV RT with the endogenous RNA template was first compared to that with poly 
(rA)-oligo(dT)io, the standard template primer used for FIV RT assays. The 
velocity of FIV RT with the endogenous RNA template was 100 % that of 
poly(rA)-oligo(dT)io template (Table 6). 
The endogenous RNA template was characterized with AZTTP, ddCTP, 
PFA, and ddTTP as inhibitors in RT assays, as described in the Materials and 
Methods section. With AZTTP, ddCTP, and ddTTP the mode of inhibition was 
competitive with respect 
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1. T7 polymerase binding sequence (underlined). 
5'-CCCAAGCTTAATACGACTCACTATAGGGAG-3' (25-MER) 
3'-GGGTTCGAATTATGCTGAGTGATATCCCTC-5' (TEMPLATE) 
2. Sense strand designated as #24. 
5'-CTCCACAGATAAATTACAGG-3' (21 MER) 
3. Primer 24' with the T7 polymerase binding sequence. 
5'-CCCAAGCTTAATACGACTCACTATAGGGAGCTCCACAGATAAATTACAGG-3'(46 MER) 
4. An overview of events. 
(parent) 5'- CAACTAGGATACTATGACCC-3' 
(primer #14)3'- GTTGATCCTATGATACTGGG-5' 
5'-CCCAAGCTTAATACGACTCACTATAGGGAGCTCCACAGATAAATTACAGG-3' (primer 24') 
3'-GAGGTATCTATTTAATGTGG-5' 
Sequence after PGR 
5'-CCCAAGCTTAATACGACTCACTATAGGGAGCTCCACAGATAAATTACAGG-CAACTAGGATACTATGACCC-3' 
3'-GGGTTCGAATTATGCTGAGTGATATCCCTAGAGGTATCTATTTAATGTGG-GTTGATCCTATGATACTGGG-5' 
Fig 8. Design of the genomic FIV RNA template. 1) represents the promoter 
sequence for T7 polymerase (underlined). 2) represents the primer (24) 5'-end of 
the amplified sequence. 3) represents the sequence of primer 24 with the T7 
promoter sequence iigated to its 5'-end (24'). 4) is an overview of events during 
PGR amplification. 
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to dNTP substrate, as with other homopolymeric template-primers (Fig 10). The 
mode of inhibition for PFA was noncompetitive, as it is with homopolymeric 
template-primers (Fig 10)(24). 
The Michaelis Menton constant. Km for substrate (dTTP) was 2.0 ± 0.1 
^M. The inhibition constants, Ki values, for AZTTP, ddTTP, and ddCTP are 
summarized in Table 7. The Ki values were between four-and five-fold higher 
than in reactions with homopolymeric RNA template-primers (24). 
Characterization of reactions with the DNA template. The velocity of recombinant 
FIV RT with the single stranded DNA template-primer was only 13% of that 
obtained with poly(rA)-oligo(dT)io (Table 6). These data demonstrate that RT has 
a higher activity with the RNA than with a DNA template, at least with this 
nucleotide sequence. The DNA and RNA endogenous templates had the same 
primer and sequence (except U vs. T in RNA vs. DNA). 
The inhibitors used to characterize the DNA template were AZTTP, ddCTP, 
ddTTP, and PFA. As found with other template-primers, the mode of inhibition 
for AZTTP, ddCTP, and ddTTP is competitive with respect to dNTP substrate (Fig 
11). The mode of inhibition for PFA is noncompetitive with respect to dNTP for 
the endogenous DNA template (Fig 11). 
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TABLE 6. TEMPLATE SPECIFICITIES OF RT ACTIVITIES 
TEMPLATE-PRIMER PERCENT ACTIVITIES* 
poly(rA)-oligo(dT)io 100 
poly(rC)-oligo(dG)io 62.2 
Endogenous RNA Template 100 
Endogenous DNA Template 13.2 
*100% is 4 pmoles of PH]-dTTP incorporated per hour. Values represent the 
mean from two or more determinations. Recombinant FIV RT was used in each 
reaction. 
TABLE 7. INHIBITION CONSTANTS FOR RT INHIBITORS IN REACTIONS WITH 
ENDOGENOUS TEMPLATES. 
Ki (nM)* 
INHIBITOR RNA TEMPLATE DNA TEMPLATE 
AZTTP 56.1 ± 9.0 90.1 ± 5 
ddCTP 23.3 ± 5 58.7 ± 6 
ddTTP 30.1 ± 0.5 21.5 ± 0.5 
PFA 1485 ± 15 709 ± 15 
* Each Ki value represents the mean value from at least six determinations. 
Recombinant FIV RT was used in each reaction. 
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Figure 10 Lineweaver-Burke plots for the inhibition of recombinant FIV RT by 
nucleotide analogues and PFA In reactions with the endogenous RNA template. 
A) Competitive Inhibition by AZTTP: 1000 nM AZTTP (A), 500 nM AZTTP (T), 
100 nM AZTTP {•) no AZTTP (•). B) Competitive inhibition by ddCTP: 200 nM 
ddCTP (•), 100 nM ddCTP (A), 50 nM ddCTP (•) no ddCTP (•) C) Competitive 
inhibition with ddTTP: 500 nM ddTTP (T), 100 nM ddTTP (A), 50 nM ddTTP (•) 
no ddTTP (•). D) Noncompetitive Inhibition with PFA: 25 jiiM PFA (T), 10 jiiM 
PFA (A), 5 uM PFA (•) no PFA (•). 
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Figure 11. Lineweaver-Burke plots for inhibition of the recombinant FIV RT by 
nucleotide analogues and PFA in reactions with the endogenous DNA template. 
A) Competitive inhibition by AZTTP: 1000 nM AZTTP (T), 500 nM AZTTP (A), 100 
nM AZTTP {•) no AZTTP (•). B) Competitive inhibition by ddCTP: 200 nM 
ddCTP (T), 100 nM ddCTP (A), 50 nM ddCTP (•) no ddCTP (•) C) Competitive 
inhibition with ddTTP: 500 nM ddTTP (T), 100 nM ddTTP (A), 50 nM ddTTP (•) 
no ddTTP (•). D) Noncompetitive inhibition with PFA: 25 jiM PFA (T), 10 ji/M 
PFA (A), 5 uM PFA (•) no PFA (•). 
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The Michaeiis Menton constant. Km for the endogenous DNA template was 2.0 
± 0.1 juM. The inhibition constants, Ki, for AZTTP, ddCTP, and ddTTP are four to 
five fold higher than with other DNA template-primers (Table 7) (24). 
Inhibition of recombinant FIV RT by SELEX ligand #53 in reaction with 
endogenous DNA and RNA template-primers. SELEX ligand #53 was further 
characterized with the endogenous DNA and RNA template-primers. The Ki 
values for inhibition of FIV RT by #53 in reactions with those template-primers 
are summarized in Table 8. Interestingly, #53 inhibited RT better with the 
endogenous templates (45 nM) than with to the homopolymeric templates (95 
nM)(Table 4). The modes of inhibition were the same as seen with the 
homopolymeric templates, noncompetitive with respectto dTTP, and competitive 
with respect to template-primer (Fig 12). 
TABLE 8. INHIBITION CONSTANTS FOR LIGAND #53 IN REACTIONS 
WITH ENDOGENOUS DNA AND RNA TEMPLATES. 
TEMPLATE VARIABLE Ki(nM)^ 
ENDOGENOUS RNA ENDOGENOUS RNA 45 ± 10 
ENDOGENOUS RNA dTTP 55 ± 5 
ENDOGENOUS DNA ENDOGENOUS DNA 49 ± 8 
ENDOGENOUS DNA dTTP 35 ± 10 
* Values represent mean from six or more determinations per value. 
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Figure 12. Lineweaver-Burke plots for inhibition of recombinant FIV RT by 
SELEX #53 in reactions with endogenous RNA and DNA templates. 
Concentrations were 200 nM #53 (•), 100 nM #53 (•), 50 nM #53 (•), and no 
#53(#). A) Competitive inhibition in reactions with variable RNA template. B) 
Noncompetitive inhibition in reactions with variable dTTP and endogenous RNA 
template. C) Competitive inhibition in reactions with variable DNA template. D) 
Noncompetitive inhibition in reactions with variable dTTP and endogenous 
DNA template. 
40 
B 
-30-20-10 0 10 20 30 
1/[Endogenous RNA Template A 
300 -
w 250 
.i 200 
150 -
260 
-0.6-0.4-0.2 0 
I  I  
0 0.2 0.4 0.6 
1/[dTTP](ijM)-i 
550 -| 
500 -
O 450 
w 400 
<D 350 
.i 300 
t 250 -
g 200 
CL 150 
^ 100 
-100 -50 0 50 100 
1/[Endogenous DNA template A26o](mM)''' 
-0.6-0.4-0.2 0.0 0.2 0.4 0.6 
1/[dTTP](ijM)-i 
41 
DISCUSSION 
This study is the first kinetic characterization of the inhibition of RT by 
SELEX ligands. It has identified SELEX ligands that are potent inhibitors of 
purified FIV RT. Of seven SELEX ligands that were tested, only two ligands, 
#53, and #60, were found to be potent inhibitors of FIV RT. These ligands are 
comparable in potency to nucleotide inhibitors of FIV RT. AZTTP has a Ki of 54 
nM using recombinant FIV RT, and the endogenous DNA template-primer 
where SELEX ligand #53 has a Ki of 45 under the same conditions. 
These FIV-RT specific ligands, like the HIV-1 RT-specific RNA ligands 
reported by Tuerk et al. (47), were selected in such a way that facilitated but did 
not demand a pseudoknot structure. The pseudoknot structure is predicted for 
the FIV, and HIV-1 template-primer binding site (4). Interestingly, none of the 
FIV RT-specific SELEX ligands formed a psuedoknot. It is possible that some 
RNA molecules with pseudoknot structures are in the selected pool; however, 
the predominant ligands did not form pseudoknots. The two SELEX ligands that 
were identified as potent inhibitors fell into different classes based upon 
structure. Ligand #60 has a Class I structure which forms a stem-loop with an 
internal bulge. #53 has a class II structure, and also forms a stem-loop with 
internal bulge, and contains two U-tracts in the region which is predicted to be 
single stranded. Ligands #53, and #60, share the ability to form a stem-loop 
with an internal bulge. This structure may be important for inhibition of FIV RT. 
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The other five SELEX ligands were much less inhibitory to FIV RT than 
#53 and #60. Interestingly some of the dissociation constants of the other five 
ligands are lower than for #53. These data suggest that there is no correlation 
between dissociation constants and inhibition constants. All ligands were 
noncompetitive with respect to nucleotide concentration suggesting that they 
bind to RT at places other than the nucleotide binding site. Because SELEX 
ligands are oligonucleotides, it is not surprising that they compete with the 
template-primer, and that they are noncompetitive with respect to nucleotide 
concentration. These data (Fig 7, and Table 4) suggest that the #53 and #60 
bind to the template-primer site. 
All previous kinetic studies of RT with RNA templates, and initial parts of 
this work, were done with homopolymer templates. Homopolymeric templates 
are adequate for studies with nucleotide analogues which compete with dNTP 
substrate. However, the SELEX ligands compete with template-primer. 
Therefore it was desirable to study more biologically relevant, natural template-
primers for further characterization of the ligands. 
The templates that were developed included DNA and RNA templates 
corresponding to a 316 base-pair fragment of the FIV genome. With these 
templates, inhibition of FIV RT by nucleotide analogues and by PFA yielded Ki 
values similar to those obtained in reactions with other heteropolymeric DNA 
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templates previously used for kinetic characterization of RT Inhibitors (6, 25). 
However, the RT activity with heteropolymeric RNA templates used In these 
studies was too low for kinetic analyses. RT activity with the endogenous DNA 
template-primer used in this study was similar to activity previously reported 
with 0X174 and M13 DNA (6). 
A few studies of HIV-1 RT have used endogenous templates, but those 
studies were focused on aspects of RT other then kinetics of inhibition by 
antivirals. Reardon (31) used short template-primers to study the kinetic 
mechanism of the RT. These were approximately 50 bases long, primed with a 
ten base oligonucleotide. Other studies with endogenous template-primers 
were used in order to study the fidelity of RT (16). These studies used long 
templates, approximately 2000-3000 bases in length, in order to study pause 
sites and stop sites In the HIV-1 genome (16). The work presented In this thesis 
is the first study of inhibition of RT by antivirals with endogenous templates. 
Interestingly, SELEX ligand #53 was a more potent inhibitor of FIV RT in 
reactions with endogenous templates than with homopolymeric templates. 
Inhibition constants from reactions with endogenous templates were about half 
of those obtained with the homopolymeric templates. Thus, SELEX ligand #53 
should be an even better Inhibitor of viral DNA synthesis than was predicted 
with the initial studies with homopolymers. The characterization of SELEX 
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ligands with endogenous templates gives insight into how well the ligand may 
inhibit FIV replication in cells. However, the template used represents only a 
small portion of the FIV genome and the reaction with RT may vary 
considerably with sequences from other parts of the genome. Klarman et al. 
(16) observed strong pause and stop sites in the HIV-1 genome, and one can 
expect similar pause and stop sites in different sequences of the FIV genome. 
These sites will affect the enzyme velocity and may alter inhibition kinetics of 
SE LEX ligands. It will be important to characterize activities of these inhibitors 
with template-primer from other parts of the FIV genome. 
RT purified from virions of wild-type and AZT-resistant FIV were both 
more sensitive than recombinant FIV RT to inhibition by SELEX ligand #53. 
This is surprising because the ligand was selected with the recombinant RT. 
We do not know the reason for this but it may be due to modifications that 
occur during virus replication that do not occur in f, coli. 
AZR-17C contains a point mutation at nucleotide 2939 that results in an 
amino acid change of a Glu to a Lys at amino acid 202 (33). This mutation in 
the FIV RT decreases sensitivity to the active form of AZT, AZTTP. However, 
this enzyme remains fully sensitive to inhibition by SELEX ligand #53. This is 
not surprising in view of the fact that the mutation responsible for AZT 
resistance is in a portion of the RT molecule located below the palm and away 
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from the template-primer binding site (as predicted from the crystal structure 
of HIV-1 RT and homology of FIV RT to the HIV-1 RT) (18, 44). It will be 
interesting to analyze other drug-resistant mutants, such as those resistant to 
ddl or ddC, which have mutations in the template-primer binding domain (2) 
with SELEX ligands. 
A crucial step in developing SELEX ligands as drugs to use in patients 
will be providing a means of delivery. There are several possible ways that an 
RNA ligand can be delivered. These include modification of the RNA ligand to 
enable cellular uptake and protection from RNases, liposome delivery, and gene 
therapy. A problem in RNA modification is the likelihood of structural changes 
that may inactivate the ligand. Liposome delivery is limited by packaging 
problems, difficulties in mass production, instability, and problems in selective 
delivery (39). A gene therapy approach seems most promising because in 
recent years it has been used for the treatment of adenosine deaminase 
deficiency with some success (19). This success was achieved using virus 
vectors for delivery and has promoted our collaboration with NeXstar, to 
develop a Crandell feline kidney cell (CrFK), which has the DNA sequence to 
encode ligand #53 inserted behind strong pol III and pol II promoters within 
the vector genome. 
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Figure 13. Preliminary data on antiviral activity of SELEX ligand #53 expressed 
in CrFK cells. On the X-axis form left to right; CrFK (no ligand), FRT1-1,1-2,1-5, 
1-7,1-9 are all CrFk cell lines that express #53 as determined by northern blot 
analysis (data not shown), (preliminary results from La Casse, Zhu and North). 
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In collaboration with Michael Lochrie of NeXstar we have constructed 36 
CrFK cell lines which express ligand #53. Our laboratory has recently shown 
that some of these cell are highly protected (99%) from FIV infection (Fig 13). 
Our lab is continuing to characterize these cell lines and the antiviral state of 
cells expressing the SELEX ligand. 
It will be important to use these cell lines that are resistant to infection 
by FIV to determine whether mutant FIV that are resistant to SELEX ligand #53 
will arise. We predict that resistance will be less frequent than with nucleoside 
analogues because of the multiple interaction sites of the ligand with the 
enzyme. 
If resistance to this ligand does arise, SELEX offers an immediate strategy 
to combat it. If a SELEX #53-resistant virus is found, the RT can be purified and 
then used for the selection of another SELEX ligand. By alternating the resistant 
enzyme and the wild-type enzyme it is conceivable that one can select a ligand 
that inhibits both the mutant and the wild-type RT. If further resistance arises 
additional ligands can be selected by SELEX. A long term goal will be to 
develop a ligand or a set of ligands that will protect against wild-type FIV and 
the major resistant mutants. 
Results of this study clearly demonstrate that potent inhibitors of FIV RT 
can be obtained via the SELEX procedure. The preliminary studies mentioned 
above demonstrate that expression of these ligands in cultured feline cells 
protects against FIV infection. SELEX offers a promising approach to AIDS 
treatment with gene therapy that can be tested in cats. 
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